Jump to content

Steatohepatitis: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
m clean up using AWB
Line 1: Line 1:
{{Infobox disease
{{Infobox medical condition
| Name = Steatohepatitis
| Name = Steatohepatitis
| Image = Steatohepatitis high mag.jpg
| Image = Steatohepatitis high mag.jpg
Line 18: Line 18:


<!-- Cause -->
<!-- Cause -->
There are two main types fatty liver disease: [[alcohol-related fatty liver disease]] and [[non-alcoholic fatty liver disease]] (NAFLD).<ref>{{cite web|title=Steatohepatitis and Steatosis (Fatty Liver)|url=http://patient.info/doctor/steatohepatitis-and-steatosis-fatty-liver|accessdate=17 May 2016|language=en-GB}}</ref> Risk factors for NAFLD include [[diabetes]], [[obesity]] and [[metabolic syndrome]]. When inflammation is present it is referred to as [[alcoholic steatohepatitis]] and [[nonalcoholic steatohepatitis]] (NASH).<ref name="pmid19065650">{{cite journal |author=Vuppalanchi R, Chalasani N |title=Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management |journal=Hepatology |volume=49 |issue=1 |pages=306–17 |date=January 2009 |pmid=19065650 |pmc=2766096 |doi=10.1002/hep.22603 |url=}}</ref> Steatohepatitis of either cause may progress to [[cirrhosis]], and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with [[lysosomal acid lipase deficiency]].{{medical citation needed|date=July 2015}}
There are two main types fatty liver disease: [[alcohol-related fatty liver disease]] and [[non-alcoholic fatty liver disease]] (NAFLD).<ref>{{cite web|title=Steatohepatitis and Steatosis (Fatty Liver)|url=http://patient.info/doctor/steatohepatitis-and-steatosis-fatty-liver|accessdate=17 May 2016|language=en-GB}}</ref> Risk factors for NAFLD include [[diabetes]], [[obesity]] and [[metabolic syndrome]]. When inflammation is present it is referred to as [[alcoholic steatohepatitis]] and [[nonalcoholic steatohepatitis]] (NASH).<ref name="pmid19065650">{{cite journal |vauthors=Vuppalanchi R, Chalasani N |title=Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management |journal=Hepatology |volume=49 |issue=1 |pages=306–17 |date=January 2009 |pmid=19065650 |pmc=2766096 |doi=10.1002/hep.22603 |url=}}</ref> Steatohepatitis of either cause may progress to [[cirrhosis]], and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with [[lysosomal acid lipase deficiency]].{{medical citation needed|date=July 2015}}


<!-- History and culture -->
<!-- History and culture -->
Line 29: Line 29:
==Non-alcoholic steatohepatitis (NASH)==
==Non-alcoholic steatohepatitis (NASH)==
{{Main|Non-alcoholic fatty liver disease}}
{{Main|Non-alcoholic fatty liver disease}}
Non-alcoholic steatohepatitis is fatty liver disease due to causes other than alcohol. No pharmacological treatment has received approval as of 2015 for NASH.<ref>{{cite journal|last1=Ratziu|first1=V|last2=Goodman|first2=Z|last3=Sanyal|first3=A|title=Current efforts and trends in the treatment of NASH.|journal=Journal of hepatology|date=April 2015|volume=62|issue=1 Suppl|pages=S65-75|pmid=25920092|doi=10.1016/j.jhep.2015.02.041}}</ref> Some studies suggest [[diet (nutrition)|diet]], [[exercise]], and [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. General recommendations include improving metabolic risk factors and reducing alcohol intake.<ref name=Adams>{{cite journal|author=Adams LA, Angulo P|title=Treatment of non-alcoholic fatty liver disease|journal=Postgrad Med J|year=2006|volume=82|pages=315–22|pmid=16679470|doi=10.1136/pgmj.2005.042200| url=http://pmj.bmj.com/cgi/content/full/82/967/315|issue=967|pmc=2563793}}</ref><ref name="pmid25274101">{{cite journal |vauthors=Veena J, Muragundla A, Sidgiddi S, Subramaniam S |title=Non-alcoholic fatty liver disease: need for a balanced nutritional source |journal=Br. J. Nutr. |volume=112 |issue=11 |pages=1858–72 |year=2014 |pmid=25274101 |doi=10.1017/S0007114514002591 |url=}}</ref> NASH was first described in 1980 in a series of patients of the [[Mayo Clinic]].<ref>{{cite journal|author=Ludwig J, Viggiano TR, McGill DB, Oh BJ|title=Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease|journal=Mayo Clin Proc|year=1980|volume=55|pmid=7382552|pages=434–438|issue=7}}</ref> Its relevance and high prevalence were recognized mainly in the 1990s. Some think NASH is a diagnosis of exclusion, and many cases may in fact be due to other causes.<ref name="pmid18192446">{{cite journal |author=Cassiman D, Jaeken J |title=NASH may be trash |journal=Gut |volume=57 |issue=2 |pages=141–4 |year=2008 |pmid=18192446 |doi=10.1136/gut.2007.123240}}</ref>
Non-alcoholic steatohepatitis is fatty liver disease due to causes other than alcohol. No pharmacological treatment has received approval as of 2015 for NASH.<ref>{{cite journal|last1=Ratziu|first1=V|last2=Goodman|first2=Z|last3=Sanyal|first3=A|title=Current efforts and trends in the treatment of NASH.|journal=Journal of hepatology|date=April 2015|volume=62|issue=1 Suppl|pages=S65-75|pmid=25920092|doi=10.1016/j.jhep.2015.02.041}}</ref> Some studies suggest [[diet (nutrition)|diet]], [[exercise]], and [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. General recommendations include improving metabolic risk factors and reducing alcohol intake.<ref name=Adams>{{cite journal|vauthors=Adams LA, Angulo P |title=Treatment of non-alcoholic fatty liver disease|journal=Postgrad Med J|year=2006|volume=82|pages=315–22|pmid=16679470|doi=10.1136/pgmj.2005.042200| url=http://pmj.bmj.com/cgi/content/full/82/967/315|issue=967|pmc=2563793}}</ref><ref name="pmid25274101">{{cite journal |vauthors=Veena J, Muragundla A, Sidgiddi S, Subramaniam S |title=Non-alcoholic fatty liver disease: need for a balanced nutritional source |journal=Br. J. Nutr. |volume=112 |issue=11 |pages=1858–72 |year=2014 |pmid=25274101 |doi=10.1017/S0007114514002591 |url=}}</ref> NASH was first described in 1980 in a series of patients of the [[Mayo Clinic]].<ref>{{cite journal|vauthors=Ludwig J, Viggiano TR, McGill DB, Oh BJ |title=Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease|journal=Mayo Clin Proc|year=1980|volume=55|pmid=7382552|pages=434–438|issue=7}}</ref> Its relevance and high prevalence were recognized mainly in the 1990s. Some think NASH is a diagnosis of exclusion, and many cases may in fact be due to other causes.<ref name="pmid18192446">{{cite journal |vauthors=Cassiman D, Jaeken J |title=NASH may be trash |journal=Gut |volume=57 |issue=2 |pages=141–4 |year=2008 |pmid=18192446 |doi=10.1136/gut.2007.123240}}</ref>


==See also==
==See also==
Line 45: Line 45:


{{Digestive system diseases}}[http://www.nashbiotechs.com '''NASHBIOTECHS An overview of NASH disease and future treatments''']
{{Digestive system diseases}}[http://www.nashbiotechs.com '''NASHBIOTECHS An overview of NASH disease and future treatments''']
⚫
* [http://www.genfit.com GENFIT]
⚫
* [http://galmedpharma.com/rd/ GALMED]


⚫
[http://www.genfit.com GENFIT]

⚫
[http://galmedpharma.com/rd/ GALMED]
[[Category:Hepatitis]]
[[Category:Hepatitis]]
[[Category:Diseases of liver]]
[[Category:Diseases of liver]]

Revision as of 04:37, 28 May 2016

Steatohepatitis
SpecialtyGastroenterology Edit this on Wikidata

Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. More deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes. [medical citation needed]

There are two main types fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD).[1] Risk factors for NAFLD include diabetes, obesity and metabolic syndrome. When inflammation is present it is referred to as alcoholic steatohepatitis and nonalcoholic steatohepatitis (NASH).[2] Steatohepatitis of either cause may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with lysosomal acid lipase deficiency.[medical citation needed]

The word is from steato-, meaning "fat" and hepatitis, meaning "inflammation of the liver".

Alcoholic steatohepatitis

Main article: Alcoholic liver disease

Chronic alcohol intake commonly causes steatohepatitis.[medical citation needed]

Non-alcoholic steatohepatitis (NASH)

Main article: Non-alcoholic fatty liver disease

Non-alcoholic steatohepatitis is fatty liver disease due to causes other than alcohol. No pharmacological treatment has received approval as of 2015 for NASH.[3] Some studies suggest diet, exercise, and antiglycemic drugs may alter the course of the disease. General recommendations include improving metabolic risk factors and reducing alcohol intake.[4][5] NASH was first described in 1980 in a series of patients of the Mayo Clinic.[6] Its relevance and high prevalence were recognized mainly in the 1990s. Some think NASH is a diagnosis of exclusion, and many cases may in fact be due to other causes.[7]

See also

References

  1. ^ "Steatohepatitis and Steatosis (Fatty Liver)". Retrieved 17 May 2016.
  2. ^ Vuppalanchi R, Chalasani N (January 2009). "Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management". Hepatology. 49 (1): 306–17. doi:10.1002/hep.22603. PMC 2766096. PMID 19065650.
  3. ^ Ratziu, V; Goodman, Z; Sanyal, A (April 2015). "Current efforts and trends in the treatment of NASH". Journal of hepatology. 62 (1 Suppl): S65-75. doi:10.1016/j.jhep.2015.02.041. PMID 25920092.
  4. ^ Adams LA, Angulo P (2006). "Treatment of non-alcoholic fatty liver disease". Postgrad Med J. 82 (967): 315–22. doi:10.1136/pgmj.2005.042200. PMC 2563793. PMID 16679470.
  5. ^ Veena J, Muragundla A, Sidgiddi S, Subramaniam S (2014). "Non-alcoholic fatty liver disease: need for a balanced nutritional source". Br. J. Nutr. 112 (11): 1858–72. doi:10.1017/S0007114514002591. PMID 25274101.
  6. ^ Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980). "Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease". Mayo Clin Proc. 55 (7): 434–438. PMID 7382552.
  7. ^ Cassiman D, Jaeken J (2008). "NASH may be trash". Gut. 57 (2): 141–4. doi:10.1136/gut.2007.123240. PMID 18192446.
  • Hepatitis C Long-Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C

NASHBIOTECHS An overview of NASH disease and future treatments

Retrieved from "https://en.wikipedia.org/w/index.php?title=Steatohepatitis&oldid=722442921"